Related Experiment Video
Updated: Jun 16, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Risk of cancer in patients with biopsy-proven giant cell arteritis
Catherine L Hill1, Antonia Cole, Maureen Rischmueller
1Rheumatology Unit, Queen Elizabeth Hospital, Woodville, Australia. catherine.hill@health.sa.gov.au
Objective:
Results of previous studies investigating the association between GCA and malignancy are conflicting. We performed a study of the risk of cancer in patients with biopsy-proven GCA.
Methods:
Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies from the major pathology laboratories in South Australia (SA). All subjects with biopsy-proven GCA were linked to the SA Cancer Registry to identify cases of cancer until 31 December 2006. Standardized incidence ratios (SIRs) for cancer were determined using the age- and gender-specific rates for SA.
Results:
There were 226 cases of biopsy-proven GCA (163 females and 63 males). Thirty-one cases were diagnosed with cancer, following the diagnosis of biopsy-proven GCA. There was no increased risk of cancer among those with biopsy-proven GCA, following the diagnosis of GCA compared with the general population (SIR 1.2; 95% CI 0.8, 1.6).
Conclusion:
This cohort study did not demonstrate any increased risk for malignancy in subjects with biopsy-proven GCA.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Aneurysm II: Clinical Manifestations and Diagnostic Studies